ArticlePostepy dermatologii i alergologii2020
Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity.
Article in Postepy dermatologii i alergologii, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Alopecia management from a comparative perspective: pharmacological and pharmaceutical insights in humans, dogs, and cats.Frontiers in veterinary science · 2026Review
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.Journal of inflammation research · 2026Review
- Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies.Biomedicines · 2025Review
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.MedComm · 2025Review
- Pathophysiology of Alopecia Areata in the Pediatric Patient.Pediatric dermatology · 2025Review
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions.Frontiers in immunology · 2023Review
- Interleukin-15 and Tumor Necrosis Factor-Dermatology research and practice · 2023Article
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.Frontiers in immunology · 2022Review
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.Drug design, development and therapy · 2022Review
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoimmune mechanisms with evident genetic background are the main components of alopecia areata (AA) pathogenesis. Interleukin 15 (IL-15) is considered as an important signalling cytokine. Its disordered expression has been linked to inflammatory autoimmune disorders.
aimThe present study aimed to evaluate serum IL-15 in active AA patients and to assess its association with patients' sex, age, and disease severity. MATERIAL AND
methodsIL-15 serum level was measured in 40 patients with active alopecia areata and 20 healthy controls using the ELISA technique. The severity of hair loss was assessed in accordance with the Severity of Alopecia Tool (SALT).
resultsA significantly higher serum level of IL-15 in AA patients than in controls was detected (
conclusionsThe elevated serum level of IL-15 in active AA patients might reflect its role in disease pathogenesis as a key signalling cytokine. Its level is correlated with disease severity. However, IL-15 is not influenced by patients' gender or age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.